Verastem, Inc. (VSTM) · Nov 19, 2026 · Exec change
CEO transition — $40,000/month for November–December 2026
Verastem’s CEO transition filing formalizes Michael Bailey’s two-month consulting handoff before he takes over January 1, with no strategic change.
Verastem is moving from the early commercialization of AVMAPKI FAKZYNJA CO-PACK toward broader clinical development of VS-7375, its KRAS G12D program, with the company already positioning Michael Bailey’s January 1, 2027 appointment as the next leadership phase.
This filing formalizes the handoff rather than changing the succession plan. Bailey will advise the current CEO and board through December 31 on the CEO transition, then assume the top job January 1.
The new information is limited to interim compensation and mechanics. Verastem will pay Bailey $40,000 per month for November and December, with payment allowed in cash, equity, or equity-based awards; the agreement can also be terminated with 30 days’ notice.
Nothing here changes the business plan, leadership timing, or operating outlook. The CEO appointment and planned retirement of Daniel Paterson were already announced in October, while Bailey’s commercial and oncology background was part of the original succession rationale.
Bottom line: This is a continuity document, not a new strategic event. It confirms a managed two-month transition with modest disclosed compensation, leaving Verastem’s underlying commercial and pipeline story unchanged.
Bailey becomes CEO on January 1, 2027
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!